Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial.
Ilenia MigliaccioDario RomagnoliFrancesca GalardiFrancesca De LucaChiara BiagioniCurigliano GiuseppeCarmen CriscitielloAlessandro Marco MinisiniErica MorettiEmanuela RisiCristina GuarducciAgostina NardoneLaura BiganzoliMatteo BenelliLuca MalorniPublished in: JCO precision oncology (2024)
and in PI3K pathway genes at T0 were associated with worse prognosis in palbociclib-treated patients. We describe the emergence of newly acquired mutations in palbociclib-treated patients, which might potentially affect subsequent treatment.
Keyphrases
- circulating tumor
- epidermal growth factor receptor
- end stage renal disease
- newly diagnosed
- ejection fraction
- estrogen receptor
- chronic kidney disease
- prognostic factors
- endothelial cells
- tyrosine kinase
- clinical trial
- gene expression
- cell free
- dna methylation
- genome wide
- single molecule
- advanced non small cell lung cancer
- transcription factor
- phase iii
- patient reported